Novartis AG (NYSE:NVS) has reportedly filed a lawsuit to block a Maryland law requiring drugmakers to offer discounts on drugs dispensed by third-party pharmacies contracting with hospitals and clinics serving low-income populations. The complaint, filed in Baltimore federal court, argues that the law, set to take effect on July 1, attempts to regulate interstate commerce outside of Maryland and conflicts with the federal 340B drug discount program. Also Read: Medicare’s Ambitious Drug Price Negotiation Plan: President Joe Biden Calls To Expand Targeted Medicines To 50 Annually by 2029. The 340B program mandates that drugmakers receiving funds ...